Elizabeth Fixman, PhD
Primary Axis:
Respiratory Health
Email:
Email contact form Research Focus:
Applying molecular techniques to animal models of asthma. Using recombinant retroviruses to generate gene-modified T cells to explore mechanisms by which T cells regulate inflammation and airway remodeling in experimental asthma. Investigating the potential therapeutic activity of a cell penetrating peptide targeting the STAT-6 transcription factor.Asthma, animal models, airway remodeling, cytokines, signal transduction, recombinant retroviruses, protein transduction, peptide
Keywords:
Asthma, animal models, airway remodeling, cytokines, signal transduction, recombinant retroviruses, protein transduction, peptide
Location:
Meakins-Christie Laboratories Publications:
Wang, Y., Li, Y., J. Shan, E.D. Fixman, and C.M. McCusker. Effective treatment of experimental ragweed-induced asthma with STAT-6-IP, a topically delivered cell penetrating peptide. Clin. Exp. Allergy (In press).
McCusker, C.T., Y. Wang, J. Shan, M. Kinyanjui, A. Villeneuve, H. Michael, and E.D. Fixman. Inhibition of experimental allergic airways disease by local application of a cell penetrating dominant negative STAT-6 peptide. J. Immunol. 179:2556-2564; 2007
Kinyanjui, M.W., M. Tamaoka, and E.D. Fixman. T-helper type 2-dependent early recruitment of antigen non-specific CD4+ T cells in experimental asthma. Clin. Exp. Allergy. 37:1455-1466; 2007
